Ocuphire Pharma, Inc. (OCUP)
NASDAQ: OCUP · IEX Real-Time Price · USD
1.980
-0.010 (-0.50%)
Jul 22, 2024, 9:57 AM EDT - Market open
Ocuphire Pharma Employees
Ocuphire Pharma had 14 employees as of December 31, 2023. The number of employees increased by 5 or 55.56% compared to the previous year.
Employees
14
Change (1Y)
5
Growth (1Y)
55.56%
Revenue / Employee
$1,357,929
Profits / Employee
-$807,214
Market Cap
52.37M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 14 | 5 | 55.56% |
Dec 31, 2022 | 9 | 1 | 12.50% |
Dec 31, 2021 | 8 | 3 | 60.00% |
Dec 31, 2020 | 5 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Inotiv | 2,055 |
Atara Biotherapeutics | 225 |
Barinthus Biotherapeutics | 130 |
Turnstone Biologics | 80 |
Aerovate Therapeutics | 51 |
LAVA Therapeutics | 37 |
vTv Therapeutics | 16 |
Reneo Pharmaceuticals | 8 |
OCUP News
- 12 days ago - Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July - GlobeNewsWire
- 6 weeks ago - Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June - GlobeNewsWire
- 2 months ago - Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - Ocuphire Pharma to Present at the Aegis Virtual Conference - GlobeNewsWire
- 3 months ago - Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting - GlobeNewsWire
- 3 months ago - First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery - GlobeNewsWire
- 4 months ago - Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris - GlobeNewsWire